[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 286
Citations 0
Global Health
July 21, 2015

Study Reveals Benefit of Early Antiretroviral Treatment

Author Affiliations

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;314(3):216. doi:10.1001/jama.2015.8118

Individuals infected with HIV should start antiretroviral therapy (ART) at diagnosis to lower their risk of developing AIDS or other health issues related to HIV infection, according to findings from an interim review of the first large-scale randomized clinical trial of early treatment, the Strategic Timing of Antiretroviral Treatment (START) trial, (http://1.usa.gov/1cZVa0l). The START study was initiated in 2009 to determine the most propitious point at which to begin ART for HIV—either early in the course of infection, when the CD4+ cell count is greater than 500 cells/mm3, or later, when it drops below 350 cells/mm3.